Viridian Therapeutics, Inc.\DE (VRDN) Cash from Financing Activities (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Cash from Financing Activities history runs 14 years deep, the most recent figure standing at $6.4 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 30.99% year-over-year to $6.4 million; the TTM figure through Mar 2026 stood at $423.9 million (up 46.23% YoY), while the FY2025 annual figure was $426.7 million, down 6.77% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $6.4 million, down from $405.9 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $405.9 million in Q4 2025, with the low at $108000.0 in Q2 2024.
• The 5-year median for Cash from Financing Activities is $10.9 million (2025), against an average of $84.6 million.
• The sharpest annual moves came in 2022 and 2024: Cash from Financing Activities surged 15202.35% in 2022, then sank 96.48% in 2024.
• Viridian Therapeutics, Inc.\DE's Cash from Financing Activities stood at $26.0 million in 2022, then surged by 664.75% to $198.9 million in 2023, then tumbled by 82.14% to $35.5 million in 2024, then surged by 1042.63% to $405.9 million in 2025, then sank by 98.43% to $6.4 million in 2026.
• Business Quant data shows VRDN's Cash from Financing Activities at $6.4 million in Q1 2026, $405.9 million in Q4 2025, and $10.9 million in Q3 2025.